[
  {
    "ts": null,
    "headline": "Can Amgen (AMGN) Keep the Earnings Surprise Streak Alive?",
    "summary": "Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
    "url": "https://finnhub.io/api/news?id=3fc75aee81ca48981f1d93f4516717c355dbd90eb100d940f89db43c1a1ebf78",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752768602,
      "headline": "Can Amgen (AMGN) Keep the Earnings Surprise Streak Alive?",
      "id": 135996901,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",
      "url": "https://finnhub.io/api/news?id=3fc75aee81ca48981f1d93f4516717c355dbd90eb100d940f89db43c1a1ebf78"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?",
    "summary": "LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.",
    "url": "https://finnhub.io/api/news?id=f68a23763a8cc6c1054870a6bb24f1e66abc3d1c622ead267d08ccc751476d51",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752759900,
      "headline": "Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?",
      "id": 135993033,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.",
      "url": "https://finnhub.io/api/news?id=f68a23763a8cc6c1054870a6bb24f1e66abc3d1c622ead267d08ccc751476d51"
    }
  },
  {
    "ts": null,
    "headline": "Thyroid Gland Disorders Diagnostics and Treatment Market Analysis Report 2024-2030 | Incorporation of AI and Advanced Therapeutics Fueling Opportunities",
    "summary": "Global Thyroid Gland Disorders Market Report 2024: Analysis of diagnostics and treatments, revenue projections (2025-2030), and segmentation by disease type, product type, and region. Discover trends, challenges, competitive landscape, ESG developments, and profiles of key players like Amgen and Pfizer. Global Thyroid Gland Disorders Diagnostics and Treatment Market Global Thyroid Gland Disorders Diagnostics and Treatment Market Dublin, July 17, 2025 (GLOBE NEWSWIRE) -- The \"Thyroid Gland Disord",
    "url": "https://finnhub.io/api/news?id=aa495739c999699f7c82f6df4be43c48da8ab65021b8e97c7bf7763ec43ce60c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752740280,
      "headline": "Thyroid Gland Disorders Diagnostics and Treatment Market Analysis Report 2024-2030 | Incorporation of AI and Advanced Therapeutics Fueling Opportunities",
      "id": 135993578,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Global Thyroid Gland Disorders Market Report 2024: Analysis of diagnostics and treatments, revenue projections (2025-2030), and segmentation by disease type, product type, and region. Discover trends, challenges, competitive landscape, ESG developments, and profiles of key players like Amgen and Pfizer. Global Thyroid Gland Disorders Diagnostics and Treatment Market Global Thyroid Gland Disorders Diagnostics and Treatment Market Dublin, July 17, 2025 (GLOBE NEWSWIRE) -- The \"Thyroid Gland Disord",
      "url": "https://finnhub.io/api/news?id=aa495739c999699f7c82f6df4be43c48da8ab65021b8e97c7bf7763ec43ce60c"
    }
  },
  {
    "ts": null,
    "headline": "Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest",
    "summary": "The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Amgen (NASDAQ:AMGN) and the rest of the therapeutics stocks fared in Q1.",
    "url": "https://finnhub.io/api/news?id=807a77cc126930315d16a8800dca3c0fce308ebd5af43fcd1354f90b57c116b9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752723066,
      "headline": "Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest",
      "id": 136005725,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Amgen (NASDAQ:AMGN) and the rest of the therapeutics stocks fared in Q1.",
      "url": "https://finnhub.io/api/news?id=807a77cc126930315d16a8800dca3c0fce308ebd5af43fcd1354f90b57c116b9"
    }
  }
]